TC21 Mediates Transformation and Cell Survival Via Activation of Phosphatidylinositol 3-kinase/Akt and NF-kappaB Signaling Pathway
Overview
Authors
Affiliations
The signaling pathways of TC21-mediated transformation and cell survival are not well-established. In this study, we have investigated the role of PI3-K/Akt signaling pathway in oncogenic-TC21-mediated transformation and cell survival. We found that oncogenic-TC21 stimulated the PI3-K activity. This was associated with the activation of Akt, a key component of PI3-K signaling pathway. We also found that TC21 interacted and formed complex with PI3-K. Mutations in the GTP-binding region of TC21, which enhanced GTP-binding potential of this protein, also stimulated its association with PI3-K, suggesting that PI3-K may preferentially interact with the GTP-bound form. Suppression of PI3-K and Akt by specific inhibitors LY294002 and Wortmannin reversed TC21-induced transformation. Likewise, inhibition of PI3-K activity by the PI3-K phosphotase PTEN reduced TC21-mediated focus formation in NIH3T3 cells. Investigation of TC21's effect on cell survival revealed that mutant-TC21 expressing cells were more resistant to etoposide- and cisplatin-induced cell death, and this was associated with the activation of anti-apoptotic protein NF-kappaB, a downstream target of Akt. Treatment of PI3-K inhibitor LY294002 significantly suppressed TC21-mediated NF-kappaB activation. In conclusion, we have identified PI3-K as an effector of TC21 and demonstrated that the PI3-K/Akt signaling pathway plays important roles in TC21-mediated transformation and cell survival.
Unmutated RRAS2 emerges as a key oncogene in post-partum-associated triple negative breast cancer.
Cifuentes C, Oeste C, Fernandez-Pisonero I, Hortal A, Garcia-Macias C, Hochart J Mol Cancer. 2024; 23(1):142.
PMID: 38987766 PMC: 11234613. DOI: 10.1186/s12943-024-02054-3.
Overexpression of wild type RRAS2, without oncogenic mutations, drives chronic lymphocytic leukemia.
Hortal A, Oeste C, Cifuentes C, Alcoceba M, Fernandez-Pisonero I, Clavain L Mol Cancer. 2022; 21(1):35.
PMID: 35120522 PMC: 8815240. DOI: 10.1186/s12943-022-01496-x.
Germline-Activating RRAS2 Mutations Cause Noonan Syndrome.
Niihori T, Nagai K, Fujita A, Ohashi H, Okamoto N, Okada S Am J Hum Genet. 2019; 104(6):1233-1240.
PMID: 31130285 PMC: 6562005. DOI: 10.1016/j.ajhg.2019.04.014.
Sanz-Rodriguez M, Gruart A, Escudero-Ramirez J, de Castro F, Delgado-Garcia J, Wandosell F J Neurosci. 2018; 38(22):5096-5110.
PMID: 29720552 PMC: 6705947. DOI: 10.1523/JNEUROSCI.3364-17.2018.
SIRT6 regulates Ras-related protein R-Ras2 by lysine defatty-acylation.
Zhang X, Spiegelman N, Nelson O, Jing H, Lin H Elife. 2017; 6.
PMID: 28406396 PMC: 5391209. DOI: 10.7554/eLife.25158.